CCL5

Overview

CCL5 (RANTES) is a CCR5 ligand chemokine that recruits effector T cells and is a core component of tumor immune infiltration signatures.

Alterations observed in the corpus

• CCL5 is one of the 20 genes in the Immunologic Constant of Rejection (ICR) signature applied to the 348-patient Sidra-LUMC AC-ICAM colon cancer cohort, grouped with the CXCR3/CCR5 chemokine ligands CXCL9 and CXCL10 PMID:37202560.

Cancer types (linked)

• Colon adenocarcinoma — CCL5 contributes to ICR-based consensus clustering that segregates ICR-high, -medium, and -low tumors with distinct overall survival PMID:37202560.

Co-occurrence and mutual exclusivity

• Co-expressed with the other ICR Th1/cytotoxic module genes (IFNG, CD8A, CD8B, CXCL9, CXCL10, GZMA/B, PRF1) in AC-ICAM PMID:37202560.

Therapeutic relevance

• No direct CCL5-targeting therapy is evaluated; the ICR module as a whole is proposed as a prognostic and potentially predictive biomarker PMID:37202560.

Open questions

• The paper treats CCL5 as a module component rather than a standalone biomarker; independent contribution is not dissected PMID:37202560.

Sources

• PMID:37202560

This page was processed by crosslinker on 2026-04-08.